Hodgkin's lymphoma Posts on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

Evaluating combined modality treatment for young adults with Hodgkin lymphoma

Posted by on Dec 7, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study determined the safety and effectiveness of combined modality treatment for young adults with classical Hodgkin lymphoma (cHL). This study concluded that this treatment approach was well-tolerated and effective for these patients. Some background Chemotherapy regimens for pediatric patients with cHL are different from...

Read More

Evaluating the risk of lung side effects in older patients with Hodgkin lymphoma

Posted by on Nov 29, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated whether older patients with Hodgkin lymphoma (HL) were at high risk for developing lung side effects when treated with bleomycin (Blenoxane). The authors found that the odds of developing lung side effects increased significantly with age in these patients. Some background For patients with HL, age is one of...

Read More

Evaluating long-term outcomes for patients with nodular lymphocyte-predominant Hodgkin lymphoma

Posted by on Nov 29, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of first-line treatment in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The authors concluded that survival among these patients was similar to that of the general population. Some background NLPHL is a rare type of Hodgkin lymphoma. When diagnosed, most...

Read More

Evaluating immune-related side effects associated with pembrolizumab.

Posted by on Nov 29, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study wanted to find out what put patients at risk of having immune-related side effects when they were treated with pembrolizumab (Keytruda). The study found that patients with a higher body mass index (BMI; a measurement of weight in relation to height) and more cycles of treatment were more likely to determine immune-related side...

Read More

Early 18F-FDG PET/CT response can predict survival in patients with Hodgkin lymphoma treated with nivolumab

Posted by on Nov 17, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate if 18F-FDG PET/CT (ePET1) imaging can predict overall survival in patients with relapsed or unresponsive (refractory) Hodgkin lymphoma who have been treated with nivolumab.   This study concluded that ePET1 assessment can predict overall survival in these patients.  Some...

Read More

Is radiotherapy after chemotherapy associated with late side effects in patients with Hodgkin’s lymphoma?

Posted by on Nov 3, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of chemotherapy plus radiotherapy for patients with early-stage classical Hodgkin's lymphoma (cHL). The authors found that this treatment combination was highly effective, with minimal late side effects. Some background Early-stage (stage 1 to 2) cHL is usually treated with a...

Read More

What factors can predict the success of stem cell transplantation for patients with lymphoma?

Posted by on Nov 3, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the risk factors associated with delayed engraftment in patients who had stem cell transplantation (SCT). The authors found that patients receiving blood transfusions, those with low platelet levels, and those given low numbers of stem cells during SCT were more likely to experience DE. Some...

Read More

The effect of uric acid levels on the outcomes of patients having an allogeneic stem cell transplant

Posted by on Nov 2, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the association of uric acid levels before a stem cell transplant and patient outcomes.  This study concluded that high uric acid levels before the transplant led to increased mortality. Some background Uric acid is a product of metabolic breakdown and is a normal component of urine. It...

Read More

Evaluating brentuximab vedotin for patients with relapsed or unresponsive Hodgkin lymphoma after SCT

Posted by on Oct 27, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the effectiveness of brentuximab vedotin (Adcetris) to chemotherapy in patients with classical Hodgkin’s lymphoma (cHL) that came back or stopped responding after a stem cell transplant (SCT). This study concluded that patients treated with brentuximab vedotin had better outcomes compared to patients in the...

Read More

Can PET scanning help guide treatment for patients with Hodgkin’s lymphoma?

Posted by on Oct 13, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated whether PET scanning after chemotherapy might help predict outcomes and guide treatment for patients with early-stage Hodgkin's lymphoma (HL). This study found that PET scanning can help identify high-risk patients after chemotherapy. Some background Chemotherapy combined with radiotherapy is the standard of...

Read More

Is tislelizumab safe and effective for patients with relapsed or refractory classical Hodgkin’s lymphoma?

Posted by on Oct 12, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined how effective and safe tislelizumab (BGB-A317) is for patients with relapsed or refractory classical Hodgkin's lymphoma (cHL). The authors concluded that most patients responded to tislelizumab but also experienced side effects. Some background cHL is often treated with chemotherapy or stem cell...

Read More